Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents of $32.83M in Q2 FY2026

Q2 FY2026 cash & equivalents was $32.83M.

Context

  • Cash & equivalents amounted to 25.6% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$32.83M-24.2% QoQ
Last fiscal yearDec 2025
$40.19M+31.2% YoY
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+31.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
40.19M USD
Year-over-year change
+31.2%
1-year CAGR
+31.2%

Cash & Equivalents vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Cash & equivalents amounts to 25.6% of total assets for ATTO, versus a peer median of 71.5%.
ATTO Competitors
Cash & Equivalents for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLTXMoonLake ImmunotherapeuticsMar 2026$298.49M USD+9.9%+103.8%74.6%
ANABAnaptysBio, Inc.Mar 2026$248.47M USD+151.9%+49.5%75.4%
ZURAZura Bio LimitedMar 2026$225.59M USD+32.3%+311.8%98.7%
ORKAOruka Therapeutics, Inc.Sep 2026$191.52M USD+109.9%+3.4%15.6%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€129.59M EUR——78.2%
ALMSAlumis Inc. Common StockJun 2026$63.71M USD-58.0%+51.8%11.4%
QTTBQ32 Bio Inc.Mar 2026$50.75M USD-22.5%+3.2%79.7%
EVMNEvommune, Inc.Mar 2026$48.32M USD+747.1%—15.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
ATTOAttovia Therapeutics, Inc.Jun 2026$32.83M USD——25.6%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M USD-5.6%-23.9%14.4%
Peer median (excluding ATTO) —+9.9%+26.4%71.5%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.